<DOC>
	<DOCNO>NCT01707745</DOCNO>
	<brief_summary>Prospective study evaluate efficacy safety intravitreal bevacizumab In retinopathy prematurity ( ROP ) . Bevacizumab 0.75 mg 0.03 ml give stage 2+ stage 3+ ROP Zone I Zone II .</brief_summary>
	<brief_title>Efficacy Safety Intravitreal Bevacizumab Threshold ROP .</brief_title>
	<detailed_description />
	<mesh_term>Retinopathy Prematurity</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>stage 2+ stage 3+ Retinopathy prematurity Zone I Zone II . Informed write consent parent guardian . Refusal give consent Critically ill neonate .</criteria>
	<gender>All</gender>
	<minimum_age>32 Weeks</minimum_age>
	<maximum_age>42 Weeks</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>